President Wants Curbs on Extensions of Drug Patents

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

WASHINGTON-President Bush has proposed policy changes to restrict the ability of drug companies to extend their patents past their expiration date. Mr. Bush said current federal laws and regulations try to balance the goals of innovation and accessibility.

WASHINGTON—President Bush has proposed policy changes to restrict the ability of drug companies to extend their patents past their expiration date. Mr. Bush said current federal laws and regulations try to balance the goals of innovation and accessibility.

New drugs have an average of 11 years patent protection before generic versions can be offered. However, companies can extend patent protection by seeking an automatic stay of expiration, which freezes the status quo until the legal questions are answered. Such stays are often based on items as seemingly trivial as the color of a bottle or a combination of ingredients unrelated to the product’s efficacy, the President said.

The FDA will issue a proposed rule that will permit only one automatic stay per generic drug application. Some patents, including those on packaging, will no longer be entitled to protections such as the 30-month automatic stay.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content